Chinabase’s commitment to Health & Advanced Manufacturing industry
This strategic move of Chinabase meets the increasing demand of the Chinese market’s growing aging population. Since 2021, we have sourced and identified numerous high-quality investment opportunities that align with our vision of impact and ventures. We aim to provide sustainable and solid support to promising healthcare projects for their seamless entry unto the dynamic Chinese market.
ChinaBase’s Revolutionizing Healthcare: Advancing Orthopedic Products through 3D Scanning and Printing
The company is located in Italy, and incubated in Faster Capital, which is a large scale global accelerator.
The company is a growth-stage SMEs with mature technology, which has developed a modular online software platform for the creation of orthopedic products through the use of 3D scanning and printing. It cross references patient’s anthropometric data, collected via photogram-metry or X-ray, with orthopedic product models of the relevant body part collected in the software's model library. The Internal Library of 3D Models platform is consisted of Musculoskeletal support and Internal prostheses .
The company is thus able to automatically develop a ready-to-print 3D model of prosthesis and musculoskeletal support tailored to patient.
ChinaBase deliverables as a Funding Partner and a Shareholder in China
Timeline: 3 months
Chinabase’s Women-Centric Healthcare: Customized Nutritional Reports and Supplements through simple Home Test
The company, formerly accelerated at EPFL Innovation Parkwithin the Tech4Eva acceleration program, a FemTech community initiative focused on technologies related to women's health. Headquartered and incubated in Monthey, Switzerland, the company specializes in providing a microbiome testing kit for rapid assessment of the vaginal bacterial and fungal ecosystem. Leveraging the test results, the company offers personalized probiotic solutions, not only addressing specific needs of fertility or menopause but also mitigating the side effects and antibiotic resistance associated from excessive antibiotic use. The product has already gained the recognition from the professional gynecological society, and is ready to expand to European market.
ChinaBase deliverables as a Funding Partner and a Shareholder
Timeline: 3-4 months
